BBS4 Double Nickase Plasmid (h): sc-403421-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- BBS4 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- BBS4 Double Nickase Plasmid (h) and BBS4 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting BBS4. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: BBS4 Antibody (1292CT845.130.218): sc-517315
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
BBS4 Double Nickase Plasmid (h) | sc-403421-NIC | 20 µg | $410.00 | |||
BBS4 Double Nickase Plasmid (h2) | sc-403421-NIC-2 | 20 µg | $410.00 |
BBS4 encodes a core component of the BBSome, a multiprotein complex that mediates ciliary membrane protein trafficking and supports primary cilium assembly and maintenance. Through coordination with intraflagellar transport machinery, BBS4 contributes to cilia-dependent signaling pathways such as Hedgehog and other receptor-mediated cascades that shape cellular polarity, sensory transduction, and developmental patterning. Disruption of BBS4 function perturbs ciliogenesis and alters ciliary signaling dynamics, linking the gene to Bardet–Biedl syndrome and broader ciliopathy-related phenotypes. As a result, BBS4 is widely studied in the context of centrosome/basal body biology, vesicular transport, and cilia-regulated metabolic and neurodevelopmental processes.
BBS4 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the BBS4 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within BBS4. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt BBS4 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of BBS4-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.